Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218849 | 1.00 | EPHX1 (0.50) | EPHX1CYP2D6SRCDPP4F2 | |
| SCHEMBL2332933 | 1.00 | EPHX1 (0.50) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL1137431 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL28645850 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL1137429 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Methane SCHEMBL6241814 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL1137441 | 0.98 | EPHX1 (0.48) | EPHX1CYP2D6SRCDPP4F2 | |
| Hydrochloric Acid SCHEMBL27583753 | 0.95 | EPHX1 (0.47) | EPHX1CYP2D6SRCDPP4F2 | |
| Acetic Acid SCHEMBL27430362 | 0.93 | ALOX5 (0.46) | EPHX1CYP2D6SRCDPP4F2 | |
| SCHEMBL7193261 | 0.87 | PTGS2 (0.52) | DPP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285504-A | Amino phenylacetamide derivative and preparation method and application thereof | 桂林医学院 | 2023-12-26 | — | — | CN | claimed |
| CN-107698484-A | A kind of preparation method of derivative of lenalidomide and application | 广东中科药物研究有限公司 | 2018-02-16 | — | — | CN | claimed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| CN-105732413-A | Synthetic process of chiral N-aromatic amino acid amide | 成都理工大学 | 2016-07-06 | — | — | CN | claimed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| EP-2546234-A1 | Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-01-16 | — | — | EP | claimed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| CN-101511352-A | Lactam containing HCV inhibitors | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | claimed |
| US-20090042858-A1 | LACTAM CONTAINING HCV INHIBITORS | BARSANTI PAUL | 2009-02-12 | — | — | US | claimed |
| EP-0034443-B1 | BETA-LACTAM ANTIBACTERIAL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1984-09-26 | — | — | EP | claimed |
| US-4407815-A | AMINO ACID DERIVATIVE ANTIBIOTICS | BEECHAM GROUP LIMITED (GB) | 1983-10-04 | — | — | US | claimed |
| EP-0061313-A2 | Bis-esters of 1,1-alkanediols with 6-beta-hydroxymethylpenicillanic acid 1,1-dioxide and beta-lactam antibiotics | PFIZER INC. (US) | 1982-09-29 | — | — | EP | claimed |
| US-4342869-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-08-03 | — | — | US | claimed |
| US-4338437-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | claimed |
| US-4338438-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | claimed |
| US-4297488-A | 7-α-Methoxy cephalosporins | MERCK & CO., INC. (US) | 1981-10-27 | — | — | US | claimed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | claimed |
| US-4072674-A | FOR CEPHALOSPORIN CONGENERS | SMITHKLINE CORPORATION (US) | 1978-02-07 | — | — | US | claimed |
| US-4062842-A | Method for preparing 7-substituted cephalosporins and 6-substituted penicillins by replacement of sulfur-containing groups | E. R. SQUIBB & SONS, INC. (US) | 1977-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | EPHX1 2026/4885CYP2D6 2277/4885SRC 1347/4885 |
| US-20090042858-A1 | LACTAM CONTAINING HCV INHIBITORS | SARS1, ZC3HAV1, ACE2 | EPHX1 2765/4885CYP2D6 1258/4885SRC 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.